Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Blood

Volumn 98, Issue 5, 2001, Pages 1326-1331

  Huhn, Dieter ^{a,b,c,d,e,f,g,h,i}   Von Schilling, Christoph ^{a,b,c,d,e,f,g,h,i}   Wilhelm, Martin ^{a,b,c,d,e,f,g,h,i}   Ho, Anthony D ^{a,b,c,d,e,f,g,h,i}   Hallek, Michael ^{a,b,c,d,e,f,g,h,i}   Kuse, Rolf ^{a,b,c,d,e,f,g,h,i}   Knauf, Wolfgang ^{a,b,c,d,e,f,g,h,i}   Riedel, Ute ^{a,b,c,d,e,f,g,h,i}   Hinke, Axel ^{a,b,c,d,e,f,g,h,i}   Srock, Stefanie ^{a,b,c,d,e,f,g,h,i}   Serke, Stefan ^{a,b,c,d,e,f,g,h,i}   Peschel, Christian ^{a,b,c,d,e,f,g,h,i}   Emmerich, Bertold ^{a,b,c,d,e,f,g,h,i}  

^a HUMBOLDT UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h ROCHE INNOVATION CENTER MUNICH   (Germany)

ⁱ WiSP Institute   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; RITUXIMAB;

ACIDOSIS; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART ARREST; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; KIDNEY FAILURE; LARYNGITIS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; NONHODGKIN LYMPHOMA; PHLEGMON; PRIORITY JOURNAL; RIGOR; SINUSITIS; SPLEEN SIZE; VOMITING;

EID: 0035469851     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1326     Document Type: Article

References (22)

1. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
2. Mc Laughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
3. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525-1527.
4. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-cd20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
5. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
6. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-cd20m monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
7. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
8. Byrd JC, Grever MR, Davis B, et al. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a feasible and active regimen [abstract]. Blood. 1999;94:704a.
9. O'Brien SM, Thomas DA, Freireich EJ, et al. Rituxan has significant activity in patients with CLL [abstract]. Blood. 1999;94:603a.
10. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77:89-91.
11. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.
12. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol. 1999;17:1962-1963.
13. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
14. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457-481.
16. Hainsworth JD, Burris HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low grade non-Hodgkin lymphoma. Blood. 2000;95:3052-3056.
17. Press O, Appelbaun F, Ledbetter J, et al. Monoclonal antibody 115 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.
18. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98:2819-2826.
19. Moreau T, Coles A, Wing MG, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119:225-237.
20. Piro LD, White CA, Grilio-Lòpez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10:655-662.
21. Davis T, Maloney D, White CA. Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with rituximab and alpha interferon: interim analysis. Proc Am Soc Clin Oncol. 1998;17:11a.
22. Vose JM, Wahl RL, Saleh M, et al. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.